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 Hepatocellular carcinoma (HCC) is the most common primary liver cancer that usually 
develops in cirrhotic patients,  except for progressive nonalcoholic fatty liver disease (NAFLD, 
where the tumor may develop also in non-cirrhotic liver) [1].   HCC is currently the leading cause 
of mortality in cirrhotic patients,  representing the fifth most common cancer and the second leading 
cause of cancer mortality worldwide [1].  Although screening programmes can allow to identify 
HCC at an earlier stage in patients at risks, still a minority of patients can survive at 5 years from 
diagnosis, despite treatment.  Current treatment options have limitations and first line drugs 
approved for systemic therapy, like sorafenib and lenvatinib, can at best offer additional 3 months 
of survival to HCC patients, emphasizing the urgent need to identify novel molecular targets to 
develop more effective therapies [1].   
 Chronic liver disease progression towards HCC development as well as HCC progression 
are highly affected by microenvironmental cues in a very complex scenario involving inter-
relationships between cells (cancer cells, tumor associated macrophages or fibroblasts and cancer 
stem cells) as well as processes or events like inflammatory response, fibrogenic progression, 
autophagy, hypoxic conditions and oxidative stress [2].  In particular, an increase in intracellular 
levels of reactive oxygen species (ROS) represents a common feature of cancer cells which is 
usually counterbalanced by an up-regulation of antioxidant defenses, particularly through the 
relevant KEAP1 (Kelch Like ECH Associated Protein 1) and  NRF2 (Nuclear factor erythroid 2 – 
Related Factor 2) - pathway [3]. In this pathway KEAP1, a E2-ligase which is normally negatively 
regulating NRF2 protein stability via ubiquitin–proteasome degradation, is inactivated under 
oxidative stress; this preserves NRF2 from degradation and allows its nuclear translocation and 
binding to antioxidant response element (ARE) sequences in the promoter of antioxidant genes, 
displacing BACH1 (BTB Domain and CNC Homolog 1,  the selective competing transcription  
repressor).  This is a critical issue since although very high levels of intracellular ROS may even 
induce cancer cell death (apoptotic or necroptotic),  lower levels of intracellular ROS sustained 
throughout the time can be pro-carcinogenic by inducing oxidative damage to DNA (favoring 
development of new mutations and cancer progression) or by altering signal transduction and 
transcriptional control,  two additional critical mechanisms underlying cancer cell response to 
microenvironmental cues.   
 In this issue of Gut an elegant experimental and clinical study by Shen et al. [4] elucidates 
the close and targetable relationships existing between the occurrence of oxidative stress, 
KEAP1/NRF2 - dependent antioxidant response and the activity of the Facilitates Chromatin 
Transcription (FACT) complex,  a histone chaperone.  As it is well known, histone chaperones play 
a fundamental role in controlling, together with ATP-dependent chromatin remodelers and histone-
modifying enzymes,  dynamic changes of chromatin like active disassembly, reassembly and 
reposition of nucleosomes, being then critical for DNA replication, DNA damage repair and gene 
transcription [5,6].  Not surprisingly, a deregulation of the interrelated activities of factors involved 
in the control of dynamic chromatin changes can affect genome stability and gene expression, 
overall promoting the development of several diseases, including cancer [5,6].     Human histone 
chaperone FACT complex  is an heterodimer composed by the two subunits SUPT16H (Suppressor 
of Ty 16 Homolog, 140 kDa) and SSRP1 (Structure Specific Recognition Protein 1,  80 kDa) that is 
involved in almost all chromatin-related processes [7].  Although FACT complex has been recently 
reported to be deregulated in breast cancer and potentially targetable [8], the mechanism(s) by 
which its deregulation may contribute to cancer progression is(are) still unknown and data on 
human HCC are lacking.   
 In their study Shen et al. [4] first analyzed HBV-associated human HCC specimens and their 
corresponding non-tumorous (NT) livers and then different human HCC cell lines and TCGA 
human HCC cohort of mixed etiology, obtaining the following major findings:  a) deregulation of 
histone chaperones was a very common event in human HCC; b) both subunits of the FACT 
complex,  SUPT16H and SSRP1, were significantly up-regulated  in human HCC specimens; c)  
SUPT16H and SSRP1 levels were also associated  with poor overall survival and disease-free 
survival of HCC patients.   The relevance of these human findings let Authors to investigate the 
pro-carcinogenic role of FACT complex.  By employing a novel CRISPR/Cas9 SAM (Synergistic 
Activation Mediator) system Authors found that simultaneous up-regulation of both SUPT16H and 
SSRP1 subunits significantly promoted cell proliferation, colony formation and cell migration in 
human MHCC97L cells. In vivo overexpression of FACT complex significantly promoted HCC 
tumor growth in the subcutaneous implantation nude mice model, suggesting that indeed FACT 
complex may operate as an oncogenic complex.   Knockout of SUPT16H or SSRP1 confirmed the 
hypothesis by significantly suppressing HCC cell proliferation, migration and colony formation in 
MHCC97L as well as HCC growth and lung metastasis in a murine orthotopic implantation model. 
Of interest, knockout of one subunit led to degradation of the other, suggesting that FACT complex 
stability in HCC strictly depend on subunits interaction.  
The analysis of promoter sequences of SUPT16H and SSRP1genes led Authors to focus on NRF2 
and BACH1 [9] and, by employing mechanistic experiments, to reveal a novel critical link between 
FACT complex and KEAP1/NRF2 pathway.  Authors provide data indicating that at protein level 
FACT complex expression is regulated by KEAP1-mediated protein degradation but at transcript 
level  FACT complex is dependent on NRF2-mediated action resulting in rapid transcription of 
target antioxidant genes like NQO1(NADPH Quinone Dehydrogenase 1), TXNRD1 (Thioredoxin 
Reductase 1) and TKT (Transketolase) in response to oxidative stress.  This means that FACT 
complex is essential for cancer cells to adapt and survive to the increased intracellular generation of 
ROS, a notion that is intrinsically relevant since KEAP1/NRF2 pathway is one of the most 
frequently mutated  in human HCC and is associated with drug resistance [10].  
A final extremely relevant and potentially translatable finding is based on experiments showing that 
treatment with Curaxin, a drug that traps FACT complex into chromatin, or knockout of FACT 
complex were both effective strategies to sensitize cancer cells to sorafenib action in HCC cell lines 
and in vivo tumor growth in subcutaneous implantation. In particular,  cotreatment of Curaxin and 
sorafenib led to increased apoptosis of cancer cells and inhibition of proliferation [4].    
 In conclusion (Figure 1), this excellent study provides compelling and mechanistic evidence, 
potentially translatable to human HCC, that cancer cells can adapt and survive to increased 
intracellular ROS levels in HCC progression as well as during sorafenib treatment (which has been 
shown to increase oxidative stress by itself) through a ROS-mediated up-regulation of FACT 
complex (associated to its increased stabilization) resulting in the acceleration of the transcription 
elongation of NRF2 and related target antioxidant genes.  Of relevance, this study indicates FACT 
complex as a reliable and specific marker for HCC detection and prognosis that can be selectively 
and efficiently targeted  by curaxin. Moreover, curaxin-mediated inhibition of FACT complex not 
only strongly compromised the oxidative stress adaptive response but also significantly sensitized 
HCC cancer cells towards the action of the first line drug sorafenib, opening the way to a novel and 
potentially more efficient strategy of therapeutic intervention for HCC patients.   
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 Figure 1. The relationships between NRF2/KEAP1 pathway, FACT complex and antioxidant response in liver 
cancer cells. (A) Liver cancer cells are commonly exposed to a significant increase of intracellular ROS 
levels, as a consequence of altered metabolism and/or of signals coming from the surrounding 
microenvironment, particularly from tumor-associated macrophages or TAM and tumor-associated 
fibroblasts or TAF (ex. cytokines, growth factors, ROS and other mediators) or in relation to hypoxic 
conditions. Very high levels of ROS can induce cancer cell injury and death whereas lower but sustained 
increase of ROS levels can result in new mutations and then potentially favor cancer progression. Upregulation 
of antioxidant genes, through NRF2 binding to target genes containing ARE sequences can favor 
survival of cancer cells. (B) In non-stressed conditions KEAP1 is bound to and maintain inactive both NRF2 
and the two subunits of FACT complex, favoring their poly-ubiquitination and degradation. (C) In the 
presence of increased intracellular ROS levels, KEAP1 is detached from target proteins and this allows: i) 
NRF2 to bind to ARE sequences in antioxidant genes to up-regulate their transcription as well as to upregulate 
transcription of the subunits of FACT complex; ii) FACT complex to operate, through nucleosome 
assembly and disassembly, by inducing transcription elongation of NRF2 and of its target antioxidant genes. 
As a net result of this scenario liver cancer cells have an increased chance to survive to oxidative stress, 
overall favoring cancer progression. (D) Curaxin, by selectively inhibiting FACT complex, can suppress HCC 
growth and sensitizes liver cancer cells to the action of sorafenib, opening the way to a novel potential 
therapeutic strategy for HCC. 
